Entries by akiibdh

AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial

Pharmacokinetic model determines optimal dose regimen for current Phase IIb recAP dose finding clinical study treating sepsis-associated acute kidney injury Bunnik, The Netherlands, 10 May 2016. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), has published data from its Phase I trial of recAP, for the potential treatment […]

AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury

AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and reports completion of first stage in Phase II trial Trial on track and FDA regulatory status may allow accelerated patient access to new drug Bunnik, The Netherlands, 26 April 2016. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant […]

AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design”

Bunnik, The Netherlands, 19 April 2016. AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) has been shortlisted for the “Most Innovative Clinical Trial Design” in the inaugural Clinical & Research Excellence Awards in Boston, organised by Informa Business Intelligence (IBI). The nomination is based on AM-Pharma’s two-part adaptive […]

AM-Pharma and Pfizer Inc. shortlisted for “Best Partnership Alliance” in 2015 Scrip Awards

Bunnik, The Netherlands, 30 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), and Pfizer Inc. have been nominated for the prestigious category of “Best Partnership Alliance” for the 11th Annual Scrip Awards, organised by Scrip Intelligence, the leading source of news and strategic analysis for the […]

AM-Pharma publishes further preclinical data on recAP to treat Acute Kidney Injury

Two papers present mode of action and pharmacokinetic model for recAP Bunnik, The Netherlands, 30 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces the publication of two papers on recAP for the potential treatment of Acute Kidney Injury (AKI). The first, published in the […]